Clinical trials
Phase 3 Carcinoma, Transitional Cell trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
10 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 2 |
| Hoffmann-La Roche | 2 |
| AstraZeneca | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Incyte Corporation | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Pfizer | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 10 |
| Urinary Bladder Neoplasms | 6 |
| Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Renal Cell | 1 |
| Neoplasm Metastasis | 1 |
| Ovarian Neoplasms | 1 |
| Urethral Neoplasms | 1 |
| Urologic Neoplasms | 1 |
Trials
Showing 1 to 10 of 10. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.